Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism: Relationships with plasma homocysteine levels

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 9, 1998, Pages 1371-1375

  Cattaneo, Marco ^a,b   Franchi, Franca ^a   Zighetti, Maddalena L ^a   Martinelli, Ida ^a   Asti, Daniela ^a   Mannucci, P Mannuccio ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Hemophilia and Thrombosis Center   (Italy)

Author keywords

Activated protein C; Homocysteine; Hypercoagulability; Protein C; Thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; HOMOCYSTEINE;

ADULT; AMINO ACID BLOOD LEVEL; ANTICOAGULATION; ARTICLE; DRUG BLOOD LEVEL; ENDOTHELIUM CELL; ENZYME ACTIVATION; FEMALE; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VEIN THROMBOSIS;

EID: 0031682568     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.9.1371     Document Type: Article

References (17)

1. Esmon CT, Ding W, Yasuhiro K, Gu J-M, Ferrel G, Regan LM, Stearns-Kurosawa DJ, Kurosawa S, Mather T, Laszik Z, Esmon NL. The protein C pathway: new insights. Thromb Haemost. 1997;78:70-74.
2. Bauer KA, Kass BL, Beeler DL, Rosenberg RD. Detection of protein C activation in humans. J Clin Invest. 1984;74:2033-2041.
3. Heeb MJ, Mosher D, Griffin JH. Inhibition and complexation of activated protein C by two major inhibitors in plasma. Blood. 1989;73:446-454.
4. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood. 1992;79:2340-2348.
5. España F, Zuazu I, Vicente V, Estellés A, Marco P, Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays: enzyme levels are proportional to total protein C levels. Thromb Haemost. 1996;75:56-61.
6. Cattaneo M. Hyperhomocysteinemia: a risk factor for arterial and venous thrombotic disease. Int J Clin Lab Res. 1997;27:139-144.
7. Harpel PC, Zhang X, Borth W. Homocysteine and hemostasis: pathogenetic mechanisms predisposing to thrombosis. J Nutr. 1996;126:1285S-1289S.
8. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895-901.
9. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest. 1991;88:1906-1914.
10. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood. 1992;79:2930-2936.
11. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood. 1996;87:3531-3544.
12. McCully KS. Homocysteine and vascular disease. Nature Med. 1996;2:386-389.
13. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res. 1993;71:337-359.
14. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insight gained from studies using markers of hemostatic system activation. Blood. 1987;70:343-350.
15. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
16. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost. 1994;72:880-886.
17. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.